Clinical trials: Influenza Vaccines
Influenza, Acute Respiratory Viral Infections
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.
This study aims to evaluate the safety and pharmacokinetic profile of the active ingredients Ingavirin forte, capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) relative to single-entity Drug Ingavirin, capsules, 90 mg following…
- Trial name
- NCT07645534
- Testing
- Ingavirin forte, capsules, 90 mg + 20 mg, Ingavirin, capsules, 90 mg
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Influenza
A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase III Study.
- Trial name
- NCT02658409
- Testing
- GC3106(quadrivalent cell-culture based influenza vaccine), Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)
- Where
- South Korea
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Respiratory Tract Disease, Influenza
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
The purpose of the study on the Prevention of Influenza and Other Wintertime Respiratory Viruses among Healthcare Professionals in Israel Effectiveness of Influenza Vaccine in Preventing Influenza Virus Infection, Missed Work…
- Trial name
- HCP (NCT03331991)
- Testing
- influenza vaccine
- Where
- 2 sites in Israel
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Abt Associates
Influenza
Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months
This study assesses immunogenicity and safety of NBP607-QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease.
- Trial name
- NCT03704740
- Testing
- NBP607-QIV, Agrippal
- Where
- South Korea
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Influenza
Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.
The present study collects data on safety and reactogenicity of the vaccine in the local target population (600 or more subjects) as per the requirement of Korean Food and Drugs Administration (KFDA).
- Trial name
- NCT00750360
- Testing
- FluarixTM
- Volunteers
- 883 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human, Infections
Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults
This Phase 2, randomized, observer-blind clinical study is evaluating 3 different priming and booster regimens with MF59-adjuvanted H5N8 and/or H5N6 cell culture-derived influenza vaccine (aH5N8c; aH5N6c).
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases
- Trial name
- NCT05874713
- Testing
- aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22
- Where
- 9 sites in United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older
The purpose of this study is to comply with the post marketing condition to the exceptional approval of Arepanrix™ in Japan and to assess the immunogenicity and safety of GSK Biologicals' H1N1 influenza vaccine healthy Japanese…
- Trial name
- NCT01114620
- Testing
- Arepanrix™
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines
The purpose of this study is to determine whether low dose flu vaccines delivered with microneedles into the skin (intradermally) are effective.
- Trial name
- NANOVAX (NCT00558649)
- Testing
- Flu Vaccine (FLUARIX®)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- NanoPass Technologies Ltd
Influenza
Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population
As influenza vaccine efficacy is reported to be lower in elderly subjects compared to healthy adults, probably as a result of immunosenescence, there is a desire to devise ways to increase the current vaccines efficacy for this…
- Trial name
- NCT00318058
- Testing
- influenza vaccine Fluarix, Adjuvanted Fluarix
- Where
- Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants
Trial to compare the safety and tolerability of one and two doses of influenza virus vaccine.
- Trial name
- NCT00192348
- Testing
- CAIV-T
- Where
- Finland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Vaccine
A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older
The purpose of this study is to confirm the safety until Day 29 after injection of a single dose of quadrivalent vaccine ASP7374 in adult subjects aged 20 or older
- Trial name
- NCT02366962
- Testing
- ASP7374
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Seasonal Influenza
Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine
This is a Phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of three dose levels (5µg, 15µg and 45µg HA) of the novel A (H1N1) influenza VLP vaccine as compared…
- Trial name
- NCT01072799
- Testing
- A/H1N1 2009 Influenza VLP Vaccine
- Where
- Mexico
- Volunteers
- 4,560 people, healthy volunteers welcome
- Sponsor
- Novavax
Healthy Volunteers
A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects
The purpose of the study is to evaluate whether administration of bimekizumab has an effect on the expected production of antibody titers to the influenza vaccine.
- Trial name
- NCT03895385
- Testing
- Bimekizumab
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Influenza
Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
Flublok was studied previously in children 6 -59 months of age and demonstrated less than satisfactory immunogenicity results, especially in the 6-36 month age group.
- Trial name
- NCT01959945
- Testing
- Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
H7N9 Influenza
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
- Trial name
- NCT01928472
- Testing
- H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, H7N9c high dose with adjuvant
- Where
- 6 sites in United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Upper Respiratory Infection
BD Veritor™ At-Home and BD Veritor™ Professional
The BD Veritor™ System is a rapid test that is testing for both COVID-19 and for Influenza This study will try to determine if the BD Veritor™ system can assist in the diagnosis of someone who has upper respiratory infection…
- Trial name
- NCT05352581
- Testing
- BD Veritor At-Home, BD Veritor Professional
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 1,146 people
- Sponsor
- Becton, Dickinson and Company
Healthy, Immunogenicity of ASP7374
A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers
This trial is designed as a blinded, randomized and parallel group study to investigate the clinically recommended dosage for ASP7374 based on the comparison of the immunogenicity and safety among two doses of subcutaneous…
- Trial name
- NCT01393951
- Testing
- ASP7374
- Where
- Japan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Influenza
Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers
This study assesses safety, tolerability and immunogenicity of NBP607QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease.
- Trial name
- NCT03826719
- Testing
- NBP607QIV, Agrippal
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Influenza
Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older
The purpose of this study is to determine the efficacy, safety and tolerability of the liquid formulation of CAIV-T against culture confirmed influenza illness in adults aged 60 years and older.
- Trial name
- NCT00217230
- Testing
- CAIV-T
- Where
- South Africa
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)
The aim of this study is to evaluate the new formulation of the influenza vaccine for the 2010-2011 Northern Hemisphere (NH) season in terms of immunogenicity and safety in the corresponding population and to check its compliance…
- Trial name
- NCT01121822
- Testing
- Influenza virus vaccine (split virion, inactivated)
- Where
- 3 sites in France
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.